Effects of Empagliflozin in chronic kidney disease on hemodialysis patients

Background: Several risk factors in chronic kidney disease (CKD) patients cause mortality; cardiovascular risk is the most important one. So, new protective treatments have to be added to the management of CKD patients; the most important one are renin angiotensin aldosterone system inhibitors (RAASI), but the latest one are sodium glucose transporter 2 inhibitors (SGLT2i). Here in this study, we tried to approve cardiac and hematologic benefits of Empagliflozine using in end stage renal disease (ESRD) on renal replacement therapy (RRT) patients. Methods: we started Empagliflozin 10 mg for 9 months in 17 hemodialysis patients. Echocardiography and serum hemoglobin to measure cardiac parameters (interventricular septum diameter {IVSD} and ejection fraction{EF%}) and serum hemoglobin (HG) levels were done at baseline and after 9 months. We included diabetic and non-diabetic patients in our study. Patients with urinary anomalies were excluded. Statistical analysis was done to the results by IBM SPSS program to evaluate the benefits. Results: We included 17 participants, 64.7 % of them were male and 35.3% were female. There ages ranges from 22 years old to 75. Results declared cardiac benefits, as interventricular septum diameter(IVSD) was reduced by mean of 0.08 cm (p.value 0.002), (Std.Deviation(0.088), and increased left ventricular ejection fraction (EF%) by mean of 2.7 % after treatment. (p.value 0.15), (Std.Deviation (7.48), and hematologic benefits, as hemoglobin increased by mean of 0.68 mg/dl (p.value 0.001), (Std.Deviation (0.67), with no important side effects. Conclusion: We concluded that, using empagliflozin in hemodialysis patients, improved cardiac function and increased hemoglobin levels with statistically significance, and may improve prognosis and quality of life.